Updates on Mesenchymal Stem Cells-Derived Extracellular Vesicles: Second Edition

Dear Colleagues,

Mesenchymal stem cells (MSCs) are adult stem cells with potent regenerative and immunoregulatory properties. MSCs in a juxtacrine, paracrine manner, through the activity of MSC-sourced growth factors, pro-angiogenic molecules, and immunomodulatory cytokines, promote the repair and regeneration of injured and inflamed tissues. MSC-derived exosomes (MSC-Exos) are nano-sized extracellular vesicles that contain MSC-sourced bioactive compounds and possess potent regenerative as well as immunomodulatory properties, similar to their parental cells. Due to their nano-sized dimension and lipid envelope, MSC-Exos easily bypass all biological barriers and deliver their cargo directly to target cells (injured parenchymal cells and immune cells), regulating their survival, phenotype, and function. Accordingly, a large number of experimental and clinical studies have demonstrated the therapeutic efficacy of MSC-Exos in the treatment of inflammatory and degenerative diseases. The therapeutic effects of MSC-Exos could be further optimized by upcoming studies that should delineate the exact molecular mechanisms responsible for their beneficial effects in particular diseases, and which should determine the optimal disease-specific therapeutic dose, treatment schedule, and route of administration. This Special Issue aims to include original data papers and reviews that describe the molecular mechanisms responsible for MSC-Exo-based tissue repair and regeneration, as well as papers monitoring the effects of MSC-Exos in preclinical models.

Dr. Carl Randall Harrell
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• MSC-Exo-based tissue repair and regeneration
• MSC-Exo-based immunomodulation
• MSC-Exo-dependent therapy of inflammatory diseases
• MSC-Exo-based therapy of degenerative diseases

• Updates on Mesenchymal Stem Cells-Derived Extracellular Vesicles in Cells (4 articles)